Evidence map›Paper›PMID 15138177›Full record

ArticleClinical and diagnostic laboratory immunology2004

Role of vav1 in the lipopolysaccharide-mediated upregulation of inducible nitric oxide synthase production and nuclear factor for interleukin-6 expression activity in murine macrophages.

Sandip A Godambe, Katherine M Knapp, Elizabeth A Meals, B Keith English

Open access · diamondAbstract read
In one paragraph

Article in Clinical and diagnostic laboratory immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Sandip A GodambeDepartment of Pediatrics, Children's Foundation Research Center, Le Bonheur Children's Medical Center, 50 N. Dunlap, Memphis, TN 38103, USA.
Katherine M Knapp
Elizabeth A Meals
B Keith English
University of Tennessee Health Science Center · USChildren’s Foundation · GBSt. Jude Children's Research Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

vav1 has been shown to play a key role in lymphocyte development and activation, but its potential importance in macrophage activation has received little attention. We have previously reported that exposure of macrophages to bacterial lipopolysaccharide (LPS) leads to increased activity of hck and other src-related tyrosine kinases and to the prompt phosphorylation of vav1 on tyrosine. In this study, we tested the role of vav1 in macrophage responses to LPS, focusing on the upregulation of nuclear factor for interleukin-6 expression (NF-IL-6) activity and inducible nitric oxide synthase (iNOS) protein accumulation in RAW-TT10 murine macrophages. We established a series of stable cell lines expressing three mutant forms of vav1 in a tetracycline-regulatable fashion: (i) a form producing a truncated protein, vavC; (ii) a form containing a point mutation in the regulatory tyrosine residue, vavYF174; and (iii) a form with an in-frame deletion of 6 amino acids required for the guanidine nucleotide exchange factor (GEF) activity of vav1 for rac family GTPases, vavGEFmt. Expression of the truncated mutant (but not the other two mutants) has been reported to interfere with T-cell activation. In contrast, we now demonstrate that expression of any of the three mutant forms of vav1 in RAW-TT10 cells consistently inhibited LPS-mediated increases in iNOS protein accumulation and NF-IL-6 activity. These data provide direct evidence for a role for vav1 in LPS-mediated macrophage activation and iNOS production and suggest that vav1 functions in part via activation of NF-IL-6. Furthermore, these findings indicate that the GEF activity of vav1 is required for its ability to mediate macrophage activation by LPS.

Indexed as

AnimalsBlotting, WesternCCAAT-Enhancer-Binding Protein-deltaCCAAT-Enhancer-Binding ProteinsCell Line, TumorGene Expression RegulationGenetic VectorsGuanine Nucleotide Exchange FactorsInterferon-gammaLipopolysaccharidesLuciferasesMacrophagesMiceMutationNitric Oxide SynthaseNitric Oxide Synthase Type IICCAAT-Enhancer-Binding Protein-deltaCCAAT-Enhancer-Binding ProteinsCebpd protein, mouseGuanine Nucleotide Exchange FactorsInterferon-gammalipopolysaccharide, Escherichia coli O111 B4LipopolysaccharidesLuciferasesNitric Oxide SynthaseNitric Oxide Synthase Type IINos2 protein, mouseOncogene ProteinsProto-Oncogene Proteins c-vavTetracyclineTranscription FactorsVav1 protein, mouse

Identifiers

PMID15138177
PMCPMC404562
OpenAlexW2133447544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.